These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 22512545)
1. Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in France. Maza A; Richard MA; Aubin F; Ortonne JP; Prey S; Bachelez H; Beylot-Barry M; Bulai-Livideanu C; Lahfa M; Nougué J; Mengual X; Le Moigne M; Lauwers-Cances V; Paul C Br J Dermatol; 2012 Sep; 167(3):643-8. PubMed ID: 22512545 [TBL] [Abstract][Full Text] [Related]
2. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. Fonia A; Jackson K; Lereun C; Grant DM; Barker JN; Smith CH Br J Dermatol; 2010 Oct; 163(4):807-16. PubMed ID: 20662837 [TBL] [Abstract][Full Text] [Related]
3. Tacalcitol in the treatment of psoriasis vulgaris: the Spanish experience. Lecha M; Mirada A; López S; Artés M; J Eur Acad Dermatol Venereol; 2005 Jul; 19(4):414-7. PubMed ID: 15987284 [TBL] [Abstract][Full Text] [Related]
4. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan. Feldman SR; Evans C; Russell MW J Dermatolog Treat; 2005 Feb; 16(1):37-42. PubMed ID: 15897166 [TBL] [Abstract][Full Text] [Related]
5. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. Abuabara K; Lee H; Kimball AB Br J Dermatol; 2011 Nov; 165(5):1066-73. PubMed ID: 21777216 [TBL] [Abstract][Full Text] [Related]
6. [Efficacy of treatment with infliximab in patients with moderate-severe psoriasis and high needs of therapy. A retrospective study of 43 patients]. Puig L Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():30-5. PubMed ID: 19080989 [TBL] [Abstract][Full Text] [Related]
7. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre. Antoniou C; Stefanaki I; Stratigos A; Moustou E; Vergou T; Stavropoulos P; Avgerinou G; Rigopoulos D; Katsambas AD Br J Dermatol; 2010 May; 162(5):1117-23. PubMed ID: 19906069 [TBL] [Abstract][Full Text] [Related]
8. [Treatment of psoriasis with biologics: a survey of dermatological and rheumatological practice at Reims University Hospital]. Adnot-Desanlis L; Brochot P; Eschard JP; Bernard P; Reguiaï Z Ann Dermatol Venereol; 2012 May; 139(5):355-62. PubMed ID: 22578339 [TBL] [Abstract][Full Text] [Related]
9. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152 [TBL] [Abstract][Full Text] [Related]
10. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: quality-of-life outcomes of a randomized controlled trial of supervised treatment of psoriasis in a day-care setting. de Korte J; van der Valk PG; Sprangers MA; Damstra RJ; Kunkeler AC; Lijnen RL; Oranje AP; de Rie MA; de Waard-van der Spek FB; Hol CW; van de Kerkhof PC Br J Dermatol; 2008 Feb; 158(2):375-81. PubMed ID: 18067483 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream. Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160 [TBL] [Abstract][Full Text] [Related]
12. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769 [TBL] [Abstract][Full Text] [Related]
13. Clinical management decisions are related to the impact of psoriasis on patient-rated quality of life. Katugampola RP; Hongbo Y; Finlay AY Br J Dermatol; 2005 Jun; 152(6):1256-62. PubMed ID: 15948990 [TBL] [Abstract][Full Text] [Related]
15. The influence of treatments in daily clinical practice on the Children's Dermatology Life Quality Index in juvenile psoriasis: a longitudinal study from the Child-CAPTURE patient registry. Oostveen AM; de Jager ME; van de Kerkhof PC; Donders AR; de Jong EM; Seyger MM Br J Dermatol; 2012 Jul; 167(1):145-9. PubMed ID: 22616669 [TBL] [Abstract][Full Text] [Related]
16. Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab. Torii H; Sato N; Yoshinari T; Nakagawa H; J Dermatol; 2012 Mar; 39(3):253-9. PubMed ID: 22211581 [TBL] [Abstract][Full Text] [Related]
17. Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients. Norlin JM; Steen Carlsson K; Persson U; Schmitt-Egenolf M Br J Dermatol; 2012 Apr; 166(4):797-802. PubMed ID: 22182212 [TBL] [Abstract][Full Text] [Related]
18. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study. Schöffski O; Augustin M; Prinz J; Rauner K; Schubert E; Sohn S; Reich K J Dtsch Dermatol Ges; 2007 Mar; 5(3):209-18. PubMed ID: 17338796 [TBL] [Abstract][Full Text] [Related]
19. Infliximab for the treatment of adults with psoriasis. Loveman E; Turner D; Hartwell D; Cooper K; Clegg A Health Technol Assess; 2009 Jun; 13 Suppl 1():55-60. PubMed ID: 19567215 [TBL] [Abstract][Full Text] [Related]
20. Methotrexate and ciclosporin combination for the treatment of severe psoriasis. Aydin F; Canturk T; Senturk N; Turanli AY Clin Exp Dermatol; 2006 Jul; 31(4):520-4. PubMed ID: 16716153 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]